Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Carcinoma, Renal Cell 6Neoplasm Metastasis 2Fallopian Tube Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Liver Neoplasms 1Glioblastoma 1Colorectal Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Paclitaxel 56Carboplatin 56Bevacizumab 43Gemcitabine 20Taxes 19pembrolizumab 15Immunoglobulin G 13Disulfides 13Topotecan 12olaparib 11Cisplatin 11niraparib 9Cyclophosphamide 9liposomal doxorubicin 8Specimen Handling 7Docetaxel 6Biopsy 6mirvetuximab soravtansine 5Nivolumab 5Magnetic Resonance Spectroscopy 5Letrozole 5Hyperthermic Intraperitoneal Chemotherapy 5Drug Therapy 5Cytoreduction Surgical Procedures 5Albumin-Bound Paclitaxel 5rucaparib 4pazopanib 4oregovomab 4Surgical Procedures, Operative 4Neoadjuvant Therapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Fallopian Tube Neoplasms × tivozanib × Clear all
NCT01853644 2021-10-12

TIVO

Northwestern University

Phase 2 Completed
31 enrolled 12 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Neoplasms, Recurrence

NCT01972516 2017-06-05

Tivozanib As Maintenance Therapy In GYN

Dana-Farber Cancer Institute

Phase 2 Terminated
4 enrolled 7 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡